Market Place
Sourcing Support
Clearmind & Dr Glitter Collaborate on Alcohol Subs Development
16 Dec 2024 //
GLOBENEWSWIRE
Clearmind Medicine Announces International Patent Application
16 Sep 2024 //
GLOBENEWSWIRE
SciSparc-Clearmind Patent For Ibogaine Combination Therapy
16 Sep 2024 //
GLOBENEWSWIRE
Clearmind And Yissum File Patent For PTSD Psychedelic Compounds
12 Sep 2024 //
GLOBENEWSWIRE
Clearmind Publishes Patent For MDMA-Based Combination Treatment
06 Sep 2024 //
GLOBENEWSWIRE
SciSparc-Clearmind Ketamine-Based Combination Patent Application Published
29 Aug 2024 //
GLOBENEWSWIRE
Clearmind Medicine Granted U.S. Patent Approval for Binge Behavior Treatment
21 Aug 2024 //
GLOBENEWSWIRE
Clearmind, Yissum Expand Collaboration With New Patent For Psychedelic Compounds
16 Aug 2024 //
GLOBENEWSWIRE
Clearmind Medicine: MEAI Shows Potential As Weight Loss Drug
06 Aug 2024 //
GLOBENEWSWIRE
Clearmind Medicine Presents Research At Psychedelic Medicine Conference
31 Jul 2024 //
GLOBENEWSWIRE
Clearmind Medicine To Source Makers For Alcohol Substitute Beverage
19 Jul 2024 //
GLOBENEWSWIRE
Clearmind Medicine Files US Patent For Metabolic Syndrome Treatment
16 Jul 2024 //
GLOBENEWSWIRE
Clearmind Medicine Gets FDA IND Approval For Alcoholism Treatment Trial
16 Jul 2024 //
GLOBENEWSWIRE
Clearmind Medicine To Present At Psychedelic Medicine - Israel 2024 Conference
12 Jul 2024 //
GLOBENEWSWIRE
Clearmind Medicine Granted Hong Kong Patent For Binge Behaviors Treatment
28 Jun 2024 //
GLOBENEWSWIRE
Clearmind Medicine Secures Global Rights To Psychedelic Compounds For PTSD
20 Jun 2024 //
GLOBENEWSWIRE
Clearmind Medicine Revolutionizes the $13 Billion NonAlcoholic Beverages Market
11 Jun 2024 //
GLOBENEWSWIRE
Clearmind Advances Psychedelic Synthetic Alcohol Beverage Product
10 May 2024 //
GLOBENEWSWIRE
Clearmind Secures Rights To Psychedelic Compounds For PTSD
07 May 2024 //
GLOBENEWSWIRE
Clearmind Applies to Cease Being a Reporting Issuer in Canada
30 Apr 2024 //
GLOBENEWSWIRE
Clearmind Licenses Generation 3.0 Psychedelic Compounds
17 Apr 2024 //
GLOBENEWSWIRE
Clearmind Medicine Files Patent for Psychedelic Eating Disorder Treatment
10 Apr 2024 //
GLOBENEWSWIRE
Clearmind Medicine CEO Issues Letter to Shareholders
09 Apr 2024 //
GLOBENEWSWIRE
SciSparc- Clearmind Collab Evolves with New International Patent Application
27 Mar 2024 //
GLOBENEWSWIRE
Clearmind Announces International Patent Application for Treating Depression
27 Mar 2024 //
GLOBENEWSWIRE
Breakthrough in Wellness: Clearmind Medicine`s Psychedelic Treatment Granted
19 Mar 2024 //
GLOBENEWSWIRE
Clearmind Medicine Received Approval for Voluntary Delisting of Common Shares
13 Mar 2024 //
GLOBENEWSWIRE
Clearmind Medicine Obtains Clearance for its Alcoholism Clinical Trial
13 Mar 2024 //
GLOBENEWSWIRE
SciSparc-Clearmind Partnership Yields Three International Patent Applications
27 Feb 2024 //
GLOBENEWSWIRE
Clearmind Medicine Receives Approval to Commence Ph I/IIa Trial of CMND-100
23 Feb 2024 //
GLOBENEWSWIRE
SciSparc and Clearmind Continue to Strengthen International Patent Portfolio
20 Feb 2024 //
GLOBENEWSWIRE
Clearmind Submits Patent Applications for Psychedelic-Based Compounds
20 Feb 2024 //
GLOBENEWSWIRE
Clearmind Medicine Receives Patent Approval for its Psychedelic Based Treatment
05 Feb 2024 //
GLOBENEWSWIRE
Clearmind Medicine Announces Agreement with Leading Israeli Research Center
01 Feb 2024 //
GLOBENEWSWIRE
Clearmind Medicine Closes US$2.4 Million Registered Direct and Private Placement
16 Jan 2024 //
GLOBENEWSWIRE
Clearmind Medicine Announces Pricing of $2.4 Million Registered Direct Placement
11 Jan 2024 //
GLOBENEWSWIRE
Clearmind Medicine Completed Type A Meeting with the FDA
10 Jan 2024 //
GLOBENEWSWIRE
SciSparc and Clearmind Medicine Reflect on Successful Collaboration in 2023
04 Jan 2024 //
GLOBENEWSWIRE
Clearmind Announces It Is In Compliance with Applicable Nasdaq Listing Standards
14 Dec 2023 //
GLOBENEWSWIRE
Clearmind Medicine Achieved Positive Results in Cocaine Addiction Treatment
05 Dec 2023 //
GLOBENEWSWIRE
Clearmind`s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
01 Dec 2023 //
GLOBENEWSWIRE
Clearmind Announces Results from Weight Loss and Metabolic Disorder Program
28 Nov 2023 //
GLOBENEWSWIRE
Clearmind to Participate in Traditional vs. Novel Psychedelics Virtual Event
27 Nov 2023 //
GLOBENEWSWIRE
Clearmind Medicine Announces 1-for-30 Reverse Share Split
21 Nov 2023 //
GLOBENEWSWIRE
Clearmind Medicine Announces Receipt of Nasdaq Delisting Notice
17 Nov 2023 //
GLOBENEWSWIRE
Clearmind Medicine Announces Shareholders Meeting Results
15 Nov 2023 //
GLOBENEWSWIRE
Clearmind Medicine to Pioneer Psychedelic Trials for Alcohol Use Disorder
09 Nov 2023 //
GLOBENEWSWIRE
Clearmind to Present at the 8th Annual Dawson James Conference on October 12th
05 Oct 2023 //
GLOBENEWSWIRE
Clearmind Medicine Closes US$2.25 Million Public Offering
18 Sep 2023 //
PRESS RELEASE
Clearmind Medicine Announces Pricing of US$2.25 Million Public Offering
14 Sep 2023 //
GLOBENEWSWIRE
Clearmind Medicine Announces Collaboration with Johns Hopkins University
06 Sep 2023 //
GLOBENEWSWIRE
Clearmind Medicine Announces Collaboration with CTS Ltd.
14 Aug 2023 //
GLOBENEWSWIRE
Clearmind Medicine Files Patent Application with USPTO for Dyskinesia
01 Aug 2023 //
GLOBENEWSWIRE
Clearmind Medicine Announces Share-Based Payment for the Company`s Consultants
17 Jul 2023 //
GLOBENEWSWIRE
Dr. Fatima Cody Stanford Joins Clearmind Medicine`s Scientific Advisory Board
11 Jul 2023 //
GLOBENEWSWIRE
Clearmind Medicine & SciSparc to Conduct Study Evaluating Combination
16 Jun 2023 //
GLOBENEWSWIRE
Clearmind Medicine to Host Investor Conference on Psychedelics for Obesity
09 Jun 2023 //
GLOBENEWSWIRE
Clearmind Announces First US Site for Phase I/IIa Trial Evaluating CMND-100
22 May 2023 //
GLOBENEWSWIRE
Clearmind Medicine Announces Receipt of Nasdaq Minimum Bid Price Notification
19 May 2023 //
GLOBENEWSWIRE
